Gilead Sciences, Inc. Director and Officer Daniel O'Day filed a Form 144 notice of proposed sale of 45,881 shares of Gilead common stock, with a notice date of October 30, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Proposed sale: 45,881 shares of Gilead Sciences common stock with an aggregate market value of $7,598,352.41, according to the filing.
  • Two acquisition sources: 15,881 shares from exercise of stock options acquired on October 30, 2026, and 30,000 shares from Performance Stock Units acquired on February 4, 2025.
  • Shares outstanding: The filing lists 1,240,338,614 shares of Gilead common stock outstanding.
  • 10b5-1 plan: The filing states the plan adoption date was February 25, 2026, and lists prior 10b5-1 sales of 15,000 shares each on August 3, September 1, and October 1, 2026.
  • Prior 3-month gross proceeds: Those three prior sales generated gross proceeds of $1,954,693.80, $2,229,592.50, and $2,218,507.50, respectively, according to the filing.
  • Exchange: Securities are listed on NASDAQ:GILD, as identified in the filing.

Daniel O'Day's Proposed Gilead Share Sale Under Rule 144

According to the Form 144 filing dated October 30, 2026, Daniel O'Day, identified as both a Director and Officer of Gilead Sciences, Inc. (NASDAQ:GILD), notified the Securities and Exchange Commission of a proposed sale of 45,881 shares of Gilead common stock. The aggregate market value of the proposed sale is listed as $7,598,352.41. The broker named in the filing is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The approximate date of sale stated in the filing is October 30, 2026.

The filing breaks down the securities to be sold into two components. The first is 15,881 shares of common stock acquired on October 30, 2026, through the exercise of stock options from the issuer, with cash payment noted. The second is 30,000 shares acquired on February 4, 2025, through Performance Stock Units from the issuer, with "N/A" listed as the nature of payment. The filing indicates the 30,000-share tranche is marked with an asterisk, which the form associates with partial cash consideration disclosures.

The filing also discloses prior sales by O'Day under a Rule 10b5-1 plan adopted on February 25, 2026. Over the three months preceding the notice date, the filing records three sales of 15,000 shares each: on August 3, 2026 (gross proceeds of $1,954,693.80), on September 1, 2026 (gross proceeds of $2,229,592.50), and on October 1, 2026 (gross proceeds of $2,218,507.50). All three prior sales are listed at the issuer's address in Foster City, California.

What Was Disclosed

Daniel O'Day, a Director and Officer of Gilead Sciences, filed a Form 144 on October 30, 2026, disclosing a proposed sale of 45,881 shares of Gilead common stock valued at $7,598,352.41, sourced from stock option exercises and Performance Stock Units, under a 10b5-1 plan adopted February 25, 2026.